Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life
详细信息 查看全文
- 作者：Katharina M. Droege (1)
Philipp S. Muether (1)
Manuel M. Hermann (1)
Albert Caramoy (1)
Ulrike Viebahn (1)
Bernd Kirchhof (1)
Sascha Fauser (1) - 关键词：Age ; related macular degeneration ; Ranibizumab ; Adherence
- 刊名：Graefe's Archive for Clinical and Experimental Ophthalmology
- 出版年：2013
- 出版时间：May 2013
- 年：2013
- 卷：251
- 期：5
- 页码：1281-1284
- 全文大小：119KB
- 参考文献：1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-431 CrossRef
2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-444 CrossRef
3. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897-908 CrossRef
4. Heimann H, Yang Y, Wachtlin J, Pauleikhoff D (2011) Differences in the treatment of exudative age-related macular degeneration in Germany and Great Britain. Ophthalmologe 108:575-84 CrossRef
5. Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S (2012) Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol May 11 [Epub ahead of print]
6. Muether PS, Hermann MM, Koch K, Fauser S (2011) Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefes Arch Clin Exp Ophthalmol 249:633-37 CrossRef
7. Abraham P, Yue H, Wilson L (2010) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150:315-24 CrossRef
8. Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE (2009) Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 147:831-37 CrossRef - 作者单位：Katharina M. Droege (1)
Philipp S. Muether (1)
Manuel M. Hermann (1)
Albert Caramoy (1)
Ulrike Viebahn (1)
Bernd Kirchhof (1)
Sascha Fauser (1)
1. Center of Ophthalmology, Department of Vitreo-Retinal Surgery, University of Cologne, 50924, Cologne, Germany - ISSN：1435-702X
文摘
Background To identify factors and problems influencing treatment adherence in patients undergoing anti-VEGF therapy for neovascular age-related macular degeneration (AMD) under real-life conditions. Methods Cross-sectional study was conducted of 95 patients receiving ranibizumab therapy on a pro re nata (PRN) regimen with monthly controls in a tertiary health care clinic. Monthly controls included best corrected visual acuity, slit-lamp examination and spectral-domain optical coherence tomography. Adherence was measured using Kaplan–Meier time-to-discontinuation analysis. Patients were asked to respond to a 16-item questionnaire covering items such as anxiety, subjective benefit, and financial issues of therapy. Results Forty-two men and 53 women were included. After a mean follow-up time of 675 days (range 63-008), adherence was 81.1?% (77/95). The mean number of follow-up visits was 19 (3-0), the mean number of intravitreal injections was ten (3-3). Seven patients withdrew from treatment due to subjective dissatisfaction with benefit. Other reasons for loss to follow-up were death in one case, serious general disease in three patients, and treatment options closer to home in five cases. Two patients cancelled further follow-up after treatment cessation due to terminal fibrosis. 62.1?% of patients were afraid of a negative examination result, whereas 19.0?% were afraid of intravitreal injections. A major problem was travel to and from the hospital (46.3?%), with 61.5?% of patients requiring escort. Conclusion Despite necessary monthly visits, patients showed a high adherence to therapy. The major problem was travel to and from the hospital. From the patients-point of view, anxiety of a negative examination result was more pronounced than fear of intraocular injections, which would be an argument for continuous injections rather than for a PRN regimen.